To determine the nature of the interaction between PI3K/AKT and HDAC inhibition in prostate adenocarcinoma and NEPC cell line models, the cell viability of C4-2B and NCI-H660 lines were determined after treatment across a dose matrix with romidepsin and AZD8186, apelisib, or ipatasertib. The gene discussed is HDAC9; the disease is prostate adenocarcinoma.